(603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Key Operating Data for Q3 2026
Filed with SSE · Stock code 603351 · · 2 pages · Chinese
Summary by 6ix AI
The report includes production, sales, and revenue figures for its main products, including synthetic lubricating base oils and pharmaceutical excipients. It also discusses price changes for major products and raw materials during the reporting period. The company assures that the information is accurate and complete, emphasizing the importance of rational investment decisions.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Nanjing Well Pharmaceutical Group Co. Ltd. on 6ix
Story so far
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Initial Repurchase of Shares through Call Auction
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Addition of a Dedicated Securities Account for Share Repurchase
Earlier from Nanjing Well Pharmaceutical
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Initial Repurchase of Shares through Call Auction
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Addition of a Dedicated Securities Account for Share Repurchase
- (603351)"Nanjing Well Pharmaceutical Group Co., Ltd."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
- Announcement on Key Operating Data for the First Half of 2026
Follow Nanjing Well Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing Well Pharmaceutical